and by others (Hiatt et al., 1952) (1973) found no correlation between hypokalaemia and urinary or serum lysozyme. Mir and his co-workers (1975a) carried out potassium balance studies in thirty-two patients with acute myeloid leukaemia; twelve had hyperkaluria but only seven of these had lysozymuria.
While the aetiological significance of lysozyme in leukaemic patients with hypokalaemia remained unsettled, some workers have examined their data to see if lysozyme has any prognostic value. Wiernik and Serpick (1969) found that patients with acute myeloid leukaemia, who had elevated initial serum muramidase levels, fared worse than those with normal or low levels. Castro, Perillie and Finch (1970) came to the opposite conclusion: they reported that patients with high serum lysozyme levels live longer than those with low levels. Currie (1976) attached prophetic significance to serum lysozyme in acute myeloid leukaemia. He was able to divide his eighty-eight patients into three groups; all nineteen patients with serum lysozyme less than 15 ,ug/ml (normal 5-1-9-7 ,ug/ml) failed to achieve remission, all ten patients with levels above 85 ,ug/ml responded to antileukaemic treatment, and the patients with serum lysozyme in between these two extremes did moderately well. Other workers have failed to confirm these findings (Mir, 1976; McCarthy et al., 1976) .
Lysozyme has been employed as a diagnostic tool by some workers: Falchuk, Perrotto and Isselbacher (1975a) found raised serum levels in Crohn's disease but not in ulcerative colitis. Pancytopenia can be a difficult diagnostic problem and serum lysozyme level has been used to differentiate between aleukaemic leukaemia (high) and aplastic anaemia (low) (Firkin, 1972) . Raised lysozyme levels have also been reported in pancytopenia of megaloblastic anaemia (Perillie, Kaplan and Finch, 1967 (Osserman and Lawlor, 1966; Muggia et al., 1969; Pickering and Catovsky, 1973) . Lysozymuria has been reported in various renal tubular disorders as a manifestation of the disease (Butler and Flyn, 1961; Kazantzis et al., 1963; Prockop and Davidson, 1964; Harrison et al., 1968) . Hypokalaemia may occur in patients with normal lysozyme; and high lysozyme levels are not always associated with low serum K levels (Pruzanski and Platts, 1973; Mir et al., 1975a) . Klockars et al. (1974) observed proximal renal tubular lesions in chloroleukaemic rats with elevated lysozyme levels, but these workers were unable to reproduce such lesions in normal rats after the intra-aortic administration of lysozyme. Other workers (Rosenthal, Maglio and Moloney, 1972; Greenberger, Rosenthal and Moloney, 1973) have demonstrated in chloroleukaemic and normal rats that only prolonged elevation in serum lysozyme causes lysozymuria and hyperkaluria. Mason, Howes and Taylor (1975) found no tubular maximum (Tm) for resorption of lysozyme in the perfused rat kidney, and lysozymuria occurred even at low perfusate levels of lysozyme.
These workers demonstrated an increased K and Na excretion as the lysozyme concentration was increased in the perfusate. Mack (1975) showed that Tm for lysozyme was about 1000 ,tg/min but lysozymuria occurred at normal filtered load of 50,ug/min.
How far can these studies in rats be extrapolated to apply to humans ? Mir et al. (1975b) correlated total glomerular filtered load with hypokalaemia in seven patients with acute myeloid leukaemia. Three of their patients developed hypokalaemia at lower than normal filtered lysozyme loads. Proximal renal tubular dysfunction has been reported in acute myeloid leukaemia in association with normal serum lysozyme levels (Mir and Delamore, 1974) . Leukaemic plasma has been found to inhibit Na efflux from erythrocytes (Mir and Bobinski, 1975) . Lysozymuria, hypokalaemia and hyperkaluria may therefore all be manifestations of widespread renal tubular dysfunction caused by some other unidentified substance of similar molecular weight, released from blast cells, which is nephrotoxic and is excreted by leukaemic patients in their urine.
